The Zhitong Finance App learned that on September 2, MSD (MRK.US) announced that Enlicitide's phase III CoralReef Lipids study to treat hypercholesterolemia had achieved positive results. The study is the largest Phase III study Enlicitide has completed to date. Previously, the drug had successfully completed two phase III studies.

Zhitongcaijing · 09/03/2025 13:17
The Zhitong Finance App learned that on September 2, MSD (MRK.US) announced that Enlicitide's phase III CoralReef Lipids study to treat hypercholesterolemia had achieved positive results. The study is the largest Phase III study Enlicitide has completed to date. Previously, the drug had successfully completed two phase III studies.